A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bédard(Princess Margaret Cancer Centre), Cristiana Sessa(Université Claude Bernard Lyon 1), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya), Angela Zubel(Novartis (Switzerland)), Zev A. Wainberg(Santa Monica College), Anastasios Stathis(Princess Margaret Cancer Centre), Kirsten Carter(Novartis (Switzerland)), Carolyn D. Britten(APLA Health), Luis Paz‐Ares(Universidad Complutense de Madrid), David Demanse(Novartis (Switzerland)), Malte Peters(Novartis (Switzerland)), Filip Jankú(The University of Texas MD Anderson Cancer Center), José Manuel Pérez-García(MedSIR (Spain)), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Johan Vansteenkiste, Heidi Nauwelaerts(Novartis (Switzerland)), Ngocdiep T. Le(GlaxoSmithKline (United States)), Dénes Csonka(Novartis (Switzerland))
Cited by 326
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k